Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patient Experience","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$1,750.0 million","newsHeadline":"Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"$2,500.0 million","upfrontCash":"$1,750.0 million","newsHeadline":"Novartis Completes Divestment of \u2018Front of Eye\u2019 Ophthalmology Assets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for 038E5L962W

    Menu

    038E5L962W

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Novartis Pharmaceuticals Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets

              Details:

              Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.

              Lead Product(s): Lifitegrast

              Therapeutic Area: Ophthalmology Product Name: Xiidra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated

              Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million

              Deal Type: Divestment September 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bausch & Lomb Incorporated

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

              Details:

              The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

              Lead Product(s): Lifitegrast

              Therapeutic Area: Ophthalmology Product Name: Xiidra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing September 11, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novartis Pharmaceuticals Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy

              Details:

              Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.

              Lead Product(s): Lifitegrast

              Therapeutic Area: Ophthalmology Product Name: Xiidra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bausch & Lomb Incorporated

              Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million

              Deal Type: Divestment June 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kedalion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patient Experience

              Details:

              Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatment of dry eye disease.

              Lead Product(s): Lifitegrast

              Therapeutic Area: Ophthalmology Product Name: Xiidra

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Interquim Lifitegrast
              Gentec SA Lifitegrast
              Close
              4
              Post Enquiry
              POST ENQUIRY